Published on 02 August 2012
Generics policies–a globally-relevant implementation challenge
Author(s): Andy Gray, MScPharm, FPS, FFIP
generics policies, transparency, WHO policy
DOI: 10.5639/gabij.2012.0103-4.027
26.474 views
Published on 02 August 2012
Author(s): Andy Gray, MScPharm, FPS, FFIP
generics policies, transparency, WHO policy
DOI: 10.5639/gabij.2012.0103-4.027
26.474 views
Published on 01 August 2012
Author(s): Luc Besançon
counterfeit medicines, healthcare professionals, risk communication
DOI: 10.5639/gabij.2012.0103-4.026
14.874 views
Published on 01 August 2012
Author(s): Keith McDonald, MSc, MRPharmS, Kowid Ho, PhD
biotechnological and chemical substances, drug substance quality, ICH Q11
DOI: 10.5639/gabij.2012.0103-4.025
35.733 views
Published on 01 August 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.024
5.278 views
Published on 04 July 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.022
7.779 views
Published on 03 July 2012
Author(s): GaBI Journal Editor
DOI: 10.5639/gabij.2012.0102.015
12.078 views
Published on 03 July 2012
Author(s): Meenu Wadhwa, PhD, Robin Thorpe, PhD, FRCPath
comparability, guidelines, non-innovator biologic, quality, safety
DOI: 10.5639/gabij.2012.0103-4.023
31.540 views
Published on 03 July 2012
Author(s): Sabine Vogler, PhD, Nina Zimmermann, MA
competition, conference, generics policies, generics uptake, medicine prices, pricing, reimbursement
DOI: 10.5639/gabij.2012.0103-4.030
14.375 views
Published on 02 July 2012
Author(s): Susanne Keitel, MD
Council of Europe, counterfeit medicines, criminalization, falsified medicines, international treaty, MEDICRIME Convention
DOI: 10.5639/gabij.2012.0103-4.029
28.000 views
Published on 02 July 2012
Author(s): Matti Aapro, MD
biosimilars, cost burden, oncology
DOI: 10.5639/gabij.2013.0202.023
27.548 views
Published on 02 July 2012
Author(s): Sabine MJM Straus, MD, PhD, Thijs J Giezen, PharmD, PhD, MSc
biologicals, biosimilars, immunogenicity, pharmacovigilance, traceability
DOI: 10.5639/gabij.2012.0103-4.033
16.809 views
Published on 02 July 2012
Author(s): Pieter Dylst, PharmD, Professor Arnold G Vulto, PharmD, PhD, FCP, Steven Simoens, MSc, PhD
Europe, generic drugs, reference pricing system, reimbursement, review
DOI: 10.5639/gabij.2012.0103-4.028
89.790 views